May 2018

Key Risk Indicators Reveal Blind Spots in Clinical Trials

By | 2018-05-16T09:02:30+01:00 May 15, 2018|Blog|Comments Off on Key Risk Indicators Reveal Blind Spots in Clinical Trials

By design, the traditional spot-checking type of audits leave a blind spot on systemic quality threats. Key Risk Indicators however, form the core of a widely applicable concept that captures all relevant risks in scope and provides project managers and QM experts targeted and objective updates on actionable issues and trends.

May 2016

Johann Proeve, Ph.D., strengthens Cyntegrity as CSO

By | 2016-11-16T18:35:32+00:00 May 24, 2016|News|0 Comments

J. Proeve, Ph.D., an expert with 35+ years of experience as Global Data Management Head at Bayer started this week as Chief Scientific Officer at Cyntegrity. He takes the responsibility of building up a proper Risk-based Monitoring (RBM) strategy for each clinical study and develop further Cyntegrity's core product RBM [...]

Apr 2016

How is RBM Adopted? Current Status.

By | 2016-11-16T18:35:34+00:00 April 10, 2016|Blog|0 Comments

The majority of companies are delaying the RBM adoption. Why? The reason lies now in the nature of innovation adoption. The main hesitations of the pragmatists to apply RBM nowadays are connected with: the general complexity of the approach the perceived risk of audit findings [...]

Dec 2015

EarlyBird Ver. 3.5 available in SandBox

By | 2016-11-16T18:35:37+00:00 December 7, 2015|News|0 Comments

Cyntegrity has updated the SandBox environment with the Version 3.5 of the RBM solution EarlyBird. The most informative & understandable graphs, robust KRIs, clear performance indicators will turn your experience with RBM analytics to a real adventure! Test it yourself. Free.

Upcoming Events

  1. SCDM 2018 ANNUAL CONFERENCE – Seattle

    September 23 - September 26
  2. PCT Europe 2018

    November 28 - November 29

Register Today!

Get Free Test Access